- Nichols L, Berg A, Rollins-Raval MA, Raval JS. Cardiac injury is a common postmortem finding in thrombotic thrombocytopenic purpura patients: is empiric cardiac monitoring and protection needed? Ther Apher Dial. 2015;19(1):87–92. doi:10.1111/1744-9987.12191.
- Morici N, Cantoni S, Panzeri F, et al. von Willebrand factor and its cleaving protease ADAMTS13 balance in coronary artery vessels: lessons learned from thrombotic thrombocytopenic purpura. A narrative review. Thromb Res. 2017;155:78–85. doi:10.1016/j.thromres.2017.05.011.
- Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496–2502. doi:10.1111/jth.15010.
- Peyvandi F, Scully M, Kremer Hovinga JA, TITAN Investigators, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016;374(6):511–522. doi:10.1056/NEJMoa1505533.
- Scully M, Cataland SR, Peyvandi F, et al. Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2019;380(4):335–346. doi:10.1056/NEJMoa1806311.
- Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085–3092. doi:10.1182/bloodadvances.2020001973.
- Picod A, Veyradier A, Coppo P. Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab? J Thromb Haemost. 2021;19(1):58–67. doi:10.1111/jth.15194.
- Paydary K, Banwell E, Tong J, Chen Y, Cuker A. Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis. Transfusion. 2020;60(9):2047–2057. doi:10.1111/trf.15954.
- Goshua G, Sinha P, Hendrickson JE, Tormey C, Bendapudi PK, Lee AI. Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood. 2021;137(7):969–976. doi:10.1182/blood.2020006052.
- Rock GA, Shumak KH, Buskard NA, et al. Canadian Apheresis Study Group. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. N Engl J Med. 1991;325(6):393–397. doi:10.1056/nejm199108083250604.
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Volume 35, 2022 - Issue 6
Case Studies
Caplacizumab in the successful management of cardiac involvement in thrombotic thrombocytopenic purpura
Amir A. Mahmouda Department of Internal Medicine, Rochester General Hospital, Rochester, New YorkCorrespondence[email protected] [email protected]
https://orcid.org/0000-0002-0630-1117
, MDhttps://orcid.org/0000-0002-0630-1117, Basant Eltaherb Department of Hematology and Bone Marrow Transplant, Ain Shams University, Cairo, Egypthttps://orcid.org/0000-0003-1255-0408
, MDhttps://orcid.org/0000-0003-1255-0408 & Anas Hashema Department of Internal Medicine, Rochester General Hospital, Rochester, New Yorkhttps://orcid.org/0000-0002-2008-7110
, MDhttps://orcid.org/0000-0002-2008-7110